Sign in
SuspendedNo phase

CLEANer Aspiration for Pulmonary Embolism

Key facts

Who runs it
Argon Medical Devices
Where
Aurora, Bartlesville, Cincinnati, Cleveland, Dallas, Fort Lauderdale, Humble, Indianapolis, Las Vegas, Plano, Tampa, Toledo, Washington D.C., and Worcester, United StatesSee the 14 sites
Trial code
Status
Suspended
People taking part
125 people, planned
Started
3 Jan 2025
Expected to end
2 Feb 2029
Type of study
Interventional
Treatments tested
  • Cleaner Pro Thrombectomy System
Record updated
21 October 2026
Why it stopped
Enrollment in the study administratively paused pending modifications to the study device design

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • At least 18 years of age at the time of consent
  • Clinical signs, symptoms, and presentation consistent with acute PE
  • Onset of PE symptoms occurred within 14 days of presentation
  • Filling defect in at least one main or lobar pulmonary artery evidenced by CTA
  • RV dysfunction on CTA or echocardiography defined as RV/LV ratio >0.9

Who cannot take part

  • tPA use within 14 days prior to baseline CTA
  • Cardiovascular or pulmonary surgery within last 7 days
  • Presentation of PE with paradoxical emboli which may be diagnosed by concurrent stroke or concurrent arterialization
  • Diagnosis of pulmonary hypertension primary type I or CTEPH; if patient does not have diagnosis of pulmonary hypertension but peak PA >70 mmHg by right heart catheterization or elevated main pulmonary artery to aorta ratio (MPA:A), up to investigator discretion
  • History of severe or chronic pulmonary hypertension
  • History of heparin-induced thrombocytopenia (HIT)
  • Recent (within six months) history of stroke, transient ischemic attack (TIA), or intracranial bleeding
  • Recent (within one month) history of active bleeding from a major organ
  • Major trauma such as head trauma, or other active intracranial, or intraspinal disease within 14 days
  • Cancer which requires active chemotherapy
  • Patients who present with cardiac arrest and/or are on extracorporeal membrane oxygenation (ECMO) or ECMO required to perform interventional procedure
  • Patients with known coagulation disorders such as antiphospholipid, Protein C, and Protein S
  • Platelets <100,000/µL
  • Serum creatinine >1.8 mg/dL
  • INR >3
  • aPTT (or PTT) >50 seconds on no anticoagulation
  • Systolic BP <90 mmHg for 15 min or the requirement of inotropic support to maintain systolic BP ≥90 mmHg
  • FiO2 requirement >40% or >6 LPM to keep oxygen saturations >90%
  • Hematocrit <28%
  • Absolute contraindication to anticoagulation
  • Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months
  • Known serious, uncontrolled sensitivity to radiographic agents
  • Life expectancy <90 days, as determined by investigator
  • Female who is pregnant
  • Intracardiac thrombus
  • Simultaneous participation in another investigational study

Where in United States

  • University of Colorado Anschutz Medical CampusAurora, United States
  • Ascension St. John Jane Phillips Medical CenterBartlesville, United States
  • University of CincinnatiCincinnati, United States
  • Cleveland ClinicCleveland, United States
  • Baylor Scott and White Heart and Vascular Hospital-DallasDallas, United States
  • Janna, LLCFort Lauderdale, United States
  • Vital Heart and VeinHumble, United States
  • Ascension St. Vincent HospitalIndianapolis, United States
  • University Medical Center of Southern NevadaLas Vegas, United States
  • Baylor Scott & White The Heart Hospital - PlanoPlano, United States
  • Baycare Health SystemTampa, United States
  • ProMedica Toledo HospitalToledo, United States
  • Medstar Health Research InstituteWashington D.C., United States
  • UMass Chan Medical SchoolWorcester, United States

About the trial

What the trial wants to find out

To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).

The group in the trial

  • Mechanical Thrombectomy via Cleaner ProTreatment being tested

    Participants will receive catheter-directed therapy via mechanical aspiration thrombectomy for the treatment of pulmonary embolism (PE) using the Cleaner Pro Thrombectomy System.

    Treatment: Cleaner Pro Thrombectomy System

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective, Multicenter Study to Evaluate the Safety and Efficacy of an Aspiration Thrombectomy System in Acute Pulmonary Embolism
Record updated
21 October 2026